& #946;-AR agonist therapy puts the brakes on oral cancer progression

(Tokyo Medical and Dental University) Oral cancer has a high mortality rate that is mainly attributed to metastasis. Researchers from Tokyo Medical and Dental University (TMDU) screened a panel of small chemical compounds for their ability to inhibit metastasis in oral cancer, identifyingβ2?AR-agonist isoxsuprine as a potential candidate. Treatment of various oral cancer cells with isoxsuprine suppressed their motility, while tumor size was significantly decreased in isoxsuprine-treated mice, suggesting thatβ-AR-agonist therapy could be an effective new treatment for oral cancer.
Source: EurekAlert! - Social and Behavioral Science - Category: International Medicine & Public Health Source Type: news